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BACKGROUND: Prescribing nonsteroidal antiinflammatory drugs (NSAIDs) is challenging because physicians have
to consider gastrointestinal (GI) and cardiovascular (CV) safety issues.
OBJECTIVE: The purpose of the study was to determine appropriate NSAID treatment strategies based on
different combinations of GI and CV risks.
METHODS: The working party comprised a multidisciplinary international panel of 19 experts. Two hundred
eighty-eight vignettes were evaluated for the appropriateness of each of six options: naproxen,
non-naproxen nonselective NSAIDs, naproxen plus proton pump inhibitor (PPI)/misoprostol,
non-naproxen nonselective NSAID plus PPI/misoprostol, cyclooxygenase-2 selective NSAID (coxib),
or coxib plus PPI/misoprostol. Using a two-stage modified Delphi process, the panel anonymously
ranked the appropriateness of each option from 1 (extremely inappropriate) to 9 (extremely
appropriate). Vignettes were considered appropriate if ≥80% of all panelists’ scores were 7–9 and
inappropriate if ≥80% of all panelists’ scores were 1–3.
RESULTS: The panel rated nonselective NSAIDs as appropriate when the patient had average GI risk (<70 yr
of age; no prior upper GI event; no corticosteroids, antithrombotic agents, anticoagulants). In
patients with GI risk factors, cotherapy with a PPI/misoprostol was appropriate. Either a
nonselective NSAID or a coxib was rated appropriate in patients with average CV risk; naproxen
was preferred in patients with high CV risk. None of the options was considered appropriate in
patients with multiple GI risk factors and high CV risk.
CONCLUSIONS: The initial choice of an NSAID (naproxen vs. others) relates to a patient’s CV risk, and the need for
therapy to decrease GI complications (PPI/misoprostol or coxibs) is determined by severity and
number of GI risk factors.
(Am J Gastroenterol 2008;103:2908–2918)
INTRODUCTION
Prescribing nonsteroidal antiinflammatory drugs (NSAIDs)
has become increasingly complex in recent years. NSAIDs
∗See list of panel members in the Appendix.
have been recognized as a major cause of gastrointestinal
(GI) complications, such as bleeding, perforation, and ob-
struction, for decades. In the United States, the direct costs
of treating ulcer complications associated with NSAID use
exceed $4 billion a year (1). Despite the availability of gastro-
protective agents, the mortality of NSAID-associated ulcer
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complications has remained high during the past decade (2).
The introduction of cyclooxygenase-2 selective inhibitors
(coxibs) had led to the hope that the antiinflammatory ac-
tion of nonselective NSAIDs could be dissociated from their
GI toxicity. However, enthusiasm for coxibs has waned be-
cause of an increase in serious cardiovascular (CV) events
with coxibs (3, 4). Emerging evidence suggests that nons-
elective NSAIDs, with the possible exception of naproxen,
also increase CV risk (5–9). In April 2005, the US Food
and Drug Administration (FDA) mandated that all NSAIDs
should include a “black box” warning to highlight the po-
tential increase in the risk of serious CV thrombotic events,
along with the warning about potentially life-threatening GI
events (10). Thus, physicians now have to consider a multi-
tude of GI and CV risk factors before prescribing NSAIDs.
Furthermore, the large amount of new data on CV and GI
risks of NSAIDs can be difficult for physicians to access and
integrate into a practical tool for patient care.
Current recommendations on the use of NSAIDs have been
developed from different perspectives including rheumatol-
ogy (11, 12), gastroenterology (13), and cardiology (14).
Previous attempts to integrate viewpoints of different spe-
cialists lacked a global representation (15). In an effort to
develop practical recommendations for physicians, a multi-
disciplinary international working party was convened to re-
view the latest clinical evidence regarding NSAID-associated
GI toxicity and CV risk and to promote multidisciplinary dis-
cussion regarding the most appropriate use of NSAIDs for
different clinical scenarios. The aim of the working party was
to generate clinical recommendations for safer NSAID pre-
scribing among patients with different levels of GI and CV
risks. A modified Delphi approach for consensus develop-
ment was used to derive final recommendations, following a
review of the literature and consideration of expert opinion.
METHODS
Convening Authority and Funding Sources
The Institute of Digestive Disease, Chinese University of
Hong Kong, convened a multidisciplinary international work-
ing party to propose clinical recommendations for safer use
of NSAIDs. The meeting was funded by an educational grant
from the Institute of Digestive Disease, Chinese University of
Hong Kong, supplemented by unrestricted educational grant
funding from the Asia Pacific offices of AstraZeneca, Pfizer,
Eisai, Altana Pharma, and Takeda (Japan). The working party
was held in Miami, Florida, on November 18 and 19, 2006.
The supporting pharmaceutical sponsors did not attend the
consensus conference. No honoraria were provided to panel
members.
Panel Selection
The panel was led by a steering committee (Francis Chan,
Neena Abraham, Loren Laine), which developed clinical vi-
gnettes and selected a multidisciplinary group of interna-
tional experts. We convened a panel of 19 members using
the following criteria: (1) expertise in NSAID- and aspirin-
related issues; (2) representation from different regions of the
world; and (3) representation of a variety of specialties in-
cluding primary care, gastroenterology, cardiology, rheuma-
tology, clinical pharmacology (two members with CV ex-
pertise), epidemiology and biostatistics (two members with
CV expertise), and health services research. Members were
from eight countries representing North America, Asia, and
Europe.
Development of Clinical Vignettes
The steering committee constructed a comprehensive series
of possible case scenarios (clinical vignettes) to reflect com-
mon clinical prescribing scenarios among patients with dif-
ferent combinations of GI and CV risk factors. We predefined
high GI risk as age ≥70 yr (16, 17); prior upper GI event (18,
19); and concomitant use of aspirin, corticosteroids, antico-
agulants, or other antiplatelet drugs (20–23) that are consid-
ered common pharmacological risk factors for GI bleeding.
High CV risk was predefined as the presence of established
CV disease (e.g., prior myocardial infarction, prior stroke,
angina) or an estimated 10-yr CV risk of greater than 20% in
patients without established CV disease (24, 25). The base-
case patient was an arthritis patient who required prolonged
(>1 month) NSAID treatment. The clinical vignettes catego-
rized patients on the basis of permutations of several clinical
factors, including (i) no prior upper GI clinical event versus
prior upper GI clinical event (defined as a bleeding or symp-
tomatic ulcer), (ii) age (<70 vs. ≥70), (iii) risk of developing
CV disease over the next 10 yr (≤20% vs. >20%), (iv) con-
comitant use of corticosteroids (none vs. corticosteroids), and
(v) other pharmacological risk factors for GI bleeding (none
vs. aspirin vs. anticoagulants vs. aspirin plus other antiplatelet
agent/anticoagulants). The permutation of these five factors
created 64 (2 × 2 × 2 × 2 × 4 = 64) different clinical
vignettes. These vignettes were then evaluated for each of
six treatment options (naproxen, a non-naproxen nonselective
NSAID [e.g., ibuprofen, diclofenac], naproxen plus a PPI or
misoprostol, a non-naproxen nonselective NSAID plus PPI
or misoprostol, a coxib, or a coxib plus PPI or misoprostol),
creating 384 (64 × 6 = 384) base vignettes. Ninety-six vi-
gnettes on concomitant use of aspirin or aspirin plus other
antiplatelet agent/anticoagulant in patients with average CV
risk were excluded because the panelists considered these vi-
gnettes to be inappropriate clinical practice and discouraged
such behavior.
We chose the above six treatment options to evaluate the
vignettes based on collective, but not conclusive data, in
the literature. Naproxen was differentiated from other non-
selective or COX-2 selective NSAIDs because current ev-
idence suggests that the CV risk is lower for high-dose
naproxen (500 mg b.i.d.) than other full-dose NSAIDs or
coxibs (6). In a meta-analysis of 21 randomized controlled
trials, naproxen was associated with a significant reduction in
the risk of myocardial infarction by 50% (95% CI 29%, 66%)
when compared with coxibs. There was no significant differ-
ence in the risk of myocardial infarction or other CV events
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between coxibs and non-naproxen nonselective NSAIDs (6).
Another meta-analysis of observational studies also found
a lower risk of myocardial infarction with naproxen com-
pared with non-naproxen nonselective NSAIDs (R.R. 0.86,
95% CI 0.75, 0.99) (9). Comparing to placebo or no NSAID
therapy, a meta-analysis of 23 observational studies showed
that the risk of CV events was not increased with naproxen
(R.R. 0.97, 95% CI, 0.87, 1.07) (7). The panel decided not to
add additional treatment options related to dose, frequency,
and duration of therapy in their deliberations because of in-
sufficient evidence and the impracticality of including mul-
tiple dosing schedules for each vignette. We differentiated
coxibs from other nonselective NSAIDs because systematic
reviews of endoscopic and GI clinical outcome trials have
shown that coxibs are superior to nonselective NSAIDs in GI
safety (26–28).
We used both PPIs and misoprostol interchangeably as
both agents have been shown to decrease the rate of endo-
scopic gastroduodenal ulcers in NSAID users (29–31). Only
misoprostol co-therapy has been shown to reduce the risk
of NSAID-associated ulcer complications in a large-scale,
placebo-controlled outcome study in an arthritis population
(32), although co-therapy with a PPI was documented to be
effective in preventing recurrent ulcer bleeding in random-
ized trials among high-risk NSAID users (33, 34). Data from
observational studies and secondary analysis of a large-scale
randomized trial also indicate that PPIs reduce the risk of
NSAID-associated ulcer bleeding (35, 36).
Literature Review
Comprehensive reviews were commissioned by the steer-
ing committee to address the GI risk of NSAIDs and cox-
ibs (by James Scheiman and Byron Cryer), the CV risk of
NSAIDs and coxibs (by Colin Baigent), the risk versus ben-
efits of aspirin and other antiplatelet drugs (by Carlo Pa-
trono), and the efficacy of co-therapies (by James Scheiman
and Byron Cryer). No formal review was commissioned
to address pharmacoeconomic or health-related quality-of-
life considerations. Using MEDLINE searches, we identi-
fied relevant articles published in English between 1980 and
September 2006. Search terms included upper gastrointesti-
nal bleeding, peptic ulcer bleeding, gastric ulcer, duodenal ul-
cer, gastroduodenal ulcer, osteoarthritis, rheumatoid arthritis,
musculoskeletal pain, NSAIDs, COX-2-selective inhibitors,
proton-pump inhibitors (PPIs), misoprostol, histamine-2 re-
ceptor antagonists, aspirin, clopidogrel, anti-platelet drugs,
corticosteroids, anti-coagulants, Helicobacter pylori, clinical
trials, observational studies, systematic reviews, and meta-
analyses.
Each member of the working party received the literature
reviews and a series of clinical vignettes. Members were
asked to read the comprehensive reviews and then to rank
the appropriateness of different therapeutic options for each
of the clinical vignettes. Summaries of the reviews were also
presented at the consensus meeting. Although panelists were
provided with doses of gastroprotective drugs from studies
of the prevention of NSAID-induced GI injury, no statements
regarding a specific dose were provided for the medications
assessed in each vignette.
The Modified Delphi Process
The Delphi method is based on anonymity, controlled feed-
back, and statistical group response and is well validated
for systematically assessing and organizing expert opinion
(37, 38). After reading the evidence-based reviews, panelists
anonymously responded to a survey representing a series of
clinical vignettes as described above, forwarding their re-
sponses to the conference organizer. Each panel member was
asked to rank the appropriateness of each of the six therapies
on a Likert scale anchored by 1 and 9, where 1 indicated
extremely inappropriate and 9 extremely appropriate. The
modified Delphi method included a face-to-face meeting of
panelists during the working party session, as previously de-
scribed (39, 40). At this group meeting, the authors of the
commissioned reviews presented their data and the group
participated in a discussion. In a feedback round, panelists
were shown the distribution of the group’s response regard-
ing each clinical vignette (i.e., controlled feedback) and dis-
cussion was promoted to provide context for the observed
results and for vignettes for which a divergence of opinion
was observed. During this feedback round, panelists were
encouraged to explain extreme positions prior to a call for
reassessment of clinical vignettes that did not meet a level of
80% agreement on the first iteration. A second anonymous
iteration of the survey was administered during the working
party meeting, including only vignettes from the first iteration
that failed to meet a level of 80% agreement. Panelists were
asked to reconsider their initial response in light of the first
round’s overall results and the preceding group discussion
of the evidence. The consensus method did not force agree-
ment. The group’s responses were summarized and results
collated for publication. Vignettes were considered appropri-
ate if ≥80% of all panelists’ scores were 7–9, inappropriate
if ≥80% of all panelists’ scores were 1–3, and uncertain if
80% agreement was not reached for scores 7–9 or 1–3.
Preparation of the Report
The steering committee drafted the manuscript, which was
then reviewed and approved by all panel members prior to
submission for peer review.
RESULTS
The panel rated therapy as appropriate in 23% of the 288 clin-
ical scenarios, inappropriate in 41%, and uncertain in 36%.
A summary of the results is shown in Tables 1–4.
Patients Without Prior GI Event and With Average CV
Risk (Table 1)
In patients aged <70, with no prior upper GI event, with
average CV risk, and no concomitant pharmacological risk
factors for GI bleeding, the panel rated the use of non-
selective NSAIDs (naproxen or non-naproxen nonselec-
tive NSAIDs) as appropriate, the use of a coxib alone
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Table 1. Treatment Strategy for Patients With No Prior Upper GI Event and Average CV Risk (10-yr Risk <20%)
Low-Dose Aspirin +
Anticoagulant Other Antiplatelet
No Aspirin or Low-Dose (e.g., Warfarin) (e.g., Clopidogrel)
Anticoagulant Aspirin Alone Alone or Anticoagulant
No Corticosteroids
Naproxen Appropriate if <70 Not applicable Inappropriate Not applicable
Uncertain if ≥70
Non-naproxen NSAID Appropriate if <70 Inappropriate
Uncertain if ≥70
Naproxen + PPI/misoprostol Inappropriate if <70 Appropriate
Appropriate if ≥70
Non-naproxen NSAID + PPI/misoprostol Inappropriate if <70 Appropriate
Appropriate if ≥70
Coxib Uncertain Uncertain
Coxib + PPI/misoprostol Inappropriate if <70 Uncertain
Uncertain if ≥70
Taking Corticosteroids
Naproxen Uncertain if <70 Not applicable Inappropriate Not applicable
Inappropriate if ≥70
Non-naproxen NSAID Uncertain if <70 Inappropriate
Inappropriate if ≥70
Naproxen + PPI/misoprostol Appropriate Appropriate
Non-naproxen NSAID + PPI/misoprostol Appropriate Appropriate if <70
Uncertain if ≥70
Coxib Uncertain Uncertain
Coxib + PPI/misoprostol Uncertain Uncertain
Results applied to both patients aged <70 and ≥70, with the exception of those results as shown.
GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal antiinflammatory drug; PPI = proton pump inhibitor; coxib = cyclooxygenase-2 selective inhibitor.
Table 2. Treatment Strategies for Patients with No Prior Upper GI Event and High CV Risk (10-yr Risk >20%)
Low-Dose Aspirin +
Anticoagulant Other Antiplatelet
No Aspirin or Low-Dose (e.g., Warfarin) (e.g., Clopidogrel)
Anticoagulant Aspirin Alone Alone or Anticoagulant
No Corticosteroids
Naproxen Appropriate if <70 Uncertain Inappropriate Inappropriate
Uncertain if ≥70
Non-naproxen Uncertain if <70 Inappropriate Inappropriate Inappropriate
NSAID Inappropriate if ≥70
Naproxen + PPI/misoprostol Inappropriate if <70 Appropriate Appropriate Appropriate
Appropriate if ≥70
Non-naproxen NSAID + PPI/misoprostol Inappropriate Uncertain Uncertain Uncertain
Coxib Inappropriate Inappropriate Inappropriate if <70 Inappropriate
Uncertain if ≥70
Coxib + PPI/misoprostol Inappropriate Inappropriate if <70 Inappropriate if <70 Uncertain
Uncertain if ≥70 Uncertain if ≥70
Taking Corticosteroids
Naproxen Uncertain if <70 Inappropriate Inappropriate Inappropriate
Inappropriate if ≥70
Non-naproxen NSAID Inappropriate Inappropriate Inappropriate Inappropriate
Naproxen + PPI/misoprostol Uncertain if <70 Appropriate Appropriate Appropriate
Appropriate if ≥70
Non-naproxen NSAID + PPI/misoprostol Uncertain Uncertain Uncertain Uncertain
Coxib Inappropriate Inappropriate Inappropriate Inappropriate
Coxib + PPI/misoprostol Inappropriate Uncertain Inappropriate if <70 Uncertain
Uncertain if ≥70
Results applied to both patients aged <70 and ≥70, with the exception of those results as shown.
GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal antiinflammatory drug; PPI = proton pump inhibitor; coxib = cyclooxygenase-2 selective inhibitor.
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Table 3. Treatment Strategies for Patients with Prior Upper GI Event and Average CV Risk (10-yr Risk <20%)
Low-Dose Aspirin +
Anticoagulant Other Antiplatelet
No Aspirin or Low-Dose (e.g., Warfarin) (e.g., Clopidogrel)
Anticoagulant Aspirin Alone Alone or Anticoagulant
No Corticosteroids
Naproxen Inappropriate Not applicable Inappropriate Not applicable
Non-naproxen NSAID Inappropriate Inappropriate
Naproxen + PPI/misoprostol Appropriate Appropriate
Non-naproxen NSAID + PPI/misoprostol Appropriate Appropriate
Coxib Uncertain Uncertain
Coxib + PPI/misoprostol Appropriate Appropriate
Taking Corticosteroids
Naproxen Inappropriate Not applicable Inappropriate Not applicable
Non-naproxen NSAID Inappropriate Inappropriate
Naproxen + PPI/misoprostol Appropriate Appropriate
Non-naproxen NSAID + PPI/misoprostol Appropriate if <70 Appropriate if <70
Uncertain if age >70 Uncertain if age >70
Coxib Uncertain Uncertain
Coxib + PPI/misoprostol Appropriate Appropriate
Results applied to both patients aged <70 and ≥70, with the exception of those results as shown.
GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal antiinflammatory drug; PPI = proton pump inhibitor; coxib = cyclooxygenase-2 selective inhibitor.
as uncertain, and the use of a nonselective NSAID or a
coxib plus a PPI/misoprostol as inappropriate. In contrast,
if the same patient was receiving concomitant corticos-
teroids and/or anticoagulants, a nonselective NSAID plus
a PPI/misoprostol was rated as appropriate. A coxib with
or without a PPI/misoprostol was still rated as uncertain,
and a nonselective NSAID alone was rated as uncertain or
inappropriate.
If the patient was at or above the age of 70, the panel rated
the use of naproxen plus a PPI/misoprostol as appropriate ir-
respective of concomitant use of anticoagulants or corticos-
teroids. Non-naproxen nonselective NSAIDs received similar
Table 4. Treatment Strategies for Patients with Prior Upper GI Event and High CV Risk (10-yr Risk >20%)
Low-Dose Aspirin +
Anticoagulant Other Antiplatelet
No Aspirin or Low-Dose (e.g., Warfarin) (e.g., Clopidogrel) or
Anticoagulant Aspirin Alone Alone Anticoagulant
No Corticosteroids
Naproxen Inappropriate Inappropriate Inappropriate Inappropriate
Non-naproxen NSAID Inappropriate Inappropriate Inappropriate Inappropriate
Naproxen + PPI/misoprostol Appropriate Appropriate Appropriate Appropriate
Non-naproxen NSAID + PPI/misoprostol Uncertain Uncertain Uncertain Uncertain
Coxib Inappropriate if <70 Inappropriate Uncertain Inappropriate
Uncertain if >70
Coxib + PPI/misoprostol Uncertain Uncertain Uncertain Uncertain
Taking Corticosteroids
Naproxen Inappropriate Inappropriate Inappropriate Inappropriate
Non-naproxen NSAID Inappropriate Inappropriate Inappropriate Inappropriate
Naproxen + PPI/misoprostol Appropriate Appropriate Appropriate Appropriate if <70
Uncertain if >70
Non-naproxen NSAID + PPI/misoprostol Uncertain Uncertain Uncertain Uncertain
Coxib Uncertain Inappropriate Uncertain Uncertain if <70
Inappropriate if >70
Coxib + PPI/misoprostol Inappropriate if <70 Uncertain Uncertain Uncertain
Uncertain if >70
Results applied to both patients aged <70 and ≥70, with the exception of those results as shown.
GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal antiinflammatory drug; PPI = proton pump inhibitor; coxib = cyclooxygenase-2 selective inhibitor.
ratings as naproxen in the elderly except that naproxen was
preferred in patients receiving concomitant corticosteroids
and anticoagulants. The use of a nonselective NSAID alone
was rated as inappropriate if the patient used concomitant
corticosteroids whereas a coxib with or without co-therapy
with a PPI/misoprostol was rated as uncertain.
Patients Without Prior GI Event and With High
CV Risk (Table 2)
Table 2 addresses the patient with high CV risk who does
not have prior upper GI event. If the patient was below the
The First International Working Party Report on Management of Patients on NSAIDs 2913
Table 5. Summary of Recommendations based on GI and CV risks
Average GI Risk High GI Risk∗
Average CV risk Nonselective NSAID alone† Nonselective NSAID + PPI/misoprostol or Coxib + PPI/misoprostol‡
High CV risk§ Naproxen (if not on aspirin)∗∗ Avoid NSAIDs if possible
Naproxen + PPI/misoprostol (if on aspirin) Naproxen + PPI/misoprostol (irrespective of concomitant use of aspirin)
GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal antiinflammatory drug; PPI = proton pump inhibitor; Coxib = cyclooxygenase-2 selective inhibitor.
∗High GI risk was defined as age ≥ 70 yr, prior upper GI event, and concomitant use of concomitant aspirin, corticosteroids, or anticoagulants.
†A nonselective NSAID includes both naproxen and a nonselective NSAID.
‡Coxib + PPI/misoprostol was recommended for patients with prior complicated upper GI event or multiple GI risk factors.
§High CV risk was defined as established coronary artery disease, any CV disease that required prophylactic low-dose aspirin, or an estimated 10-year CV risk of greater than 20%.
∗∗In clinical practice, patients may not take aspirin though it is clinically indicated.
age of 70 and did not have concomitant pharmacological risk
factors for GI bleeding, the panel rated the use of naproxen as
appropriate, the use of a non-naproxen nonselective NSAID
as uncertain, and the use of a coxib as inappropriate. Co-
therapy with a PPI/misoprostol was mostly rated as inap-
propriate. If the same patient was receiving combinations of
corticosteroids and low-dose aspirin, anticoagulants, or mul-
tiple antiplatelet agents/anticoagulants, the use of naproxen
plus a PPI/misoprostol was rated as appropriate.
In contrast, if the same patient with no prior GI event but
high CV risk was at or above the age of 70, naproxen plus
a PPI/misoprostol was rated as appropriate, irrespective of
concomitant use of low-dose aspirin, anticoagulants, corti-
costeroids, or combinations of low-dose aspirin and other
antiplatelet agents or anticoagulants. A coxib with or without
a PPI/misoprostol was rated as either uncertain or inappro-
priate.
Patients With Prior GI Event and Average
CV Risk (Table 3)
Table 3 addresses the patient with a prior upper GI event and
average CV risk. The panel’s ratings were virtually identical
whether the patient was <70 or ≥70 yr. With or without any
concomitant pharmacological risk factors for GI bleeding,
the panel rated the use of either a nonselective NSAID plus
a PPI/misoprostol or a coxib plus a PPI/misoprostol as ap-
propriate, the use of a nonselective NSAID as inappropriate,
and the use of a coxib as uncertain. One exception was that
non-naproxen nonselective NSAIDs plus a PPI/misoprostol
was rated uncertain for patients aged ≥70 yr who received
concomitant corticosteroids.
Patients With Prior GI Event and High CV Risk (Table 4)
Table 4 addresses the patient with a prior upper GI event
and high CV risk. If the patient is below the age of 70, and
with or without concomitant pharmacological risk factors
for GI bleeding, the panel rated the use of naproxen plus a
PPI/misoprostol as appropriate, a nonselective NSAID alone
as inappropriate, either a non-naproxen NSAID or a coxib
plus a PPI/misoprostol as uncertain, and a coxib with or with-
out co-therapy with a PPI/misoprostol as either uncertain or
inappropriate. If the same patient was at or above the age
of 70, the panel’s ratings were virtually identical. One no-
table exception was the scenario in which the older patient
was also receiving concomitant corticosteroids, low-dose as-
pirin, and other antiplatelet agents or anticoagulants. In this
scenario, the panel could not identify any treatment strategy
as appropriate.
Summary of Appropriate Management Strategies
Table 5 summarizes the appropriate treatment strategies ac-
cording to the patient’s GI and CV risk, using a 2 × 2 table.
For patients with average GI risk and average CV risk, the
panel rated the use of a nonselective NSAID alone as appro-
priate. In patients with high GI risk but average CV risk, ei-
ther a nonselective NSAID plus a PPI/misoprostol or a coxib
plus a PPI/misoprostol was rated as appropriate. Coxib plus a
PPI/misoprostol was preferred in patients with prior compli-
cated upper GI event or multiple GI risk factors. In patients
with high CV risk but average GI risk, the panel rated the
use of naproxen alone as appropriate for those who did not
use aspirin. If the patient was receiving prophylactic aspirin,
naproxen plus a PPI/misoprostol was rated as appropriate. In
patients with high CV and high GI risk, the panel rated the use
of naproxen plus a PPI/misoprostol as appropriate irrespec-
tive of whether the patient was receiving concomitant aspirin.
Although corticosteroid co-therapy increases the risk of GI
events in NSAID users, the presence or absence of corticos-
teroid use in the vignettes had little effect on the panelists’
votes. Therefore, corticosteroid use was not included in our
final summary recommendations.
DISCUSSION
For the first time, a multidisciplinary international expert
panel used a validated, systematic approach to the develop-
ment of consensus clinical recommendations based on cur-
rent best evidence for the appropriate use of nonselective
NSAIDs, coxibs, and prophylactic PPI or misoprostol among
patients with different combinations of GI and CV risk fac-
tors. The panel rated 288 separate clinical scenarios, which
reflects the complexity and controversy surrounding the use
of these agents. Despite the large number of scenarios, we
were able to identify common themes that allowed the devel-
opment of practical recommendations for clinicians.
The recommendations can be used to focus on patient char-
acteristics (GI and CV risk factors) and identify which ther-
apeutic options are appropriate for specific combinations of
patient characteristics.
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Figure 1. Management algorithm of patients on NSAIDs and aspirin. GI = gastrointestinal; CV = cardiovascular; NSAID = nonsteroidal
antiinflammatory drug; PPI = proton pump inhibitor; coxib = cyclooxygenase-2 selective inhibitor. ∗High GI risk was defined as age ≥70
yr, prior upper GI event, and concomitant use of concomitant aspirin, corticosteroids, or anticoagulants. ∗∗Coxib + PPI/misoprostol was
recommended for patients with prior complicated upper GI event or multiple GI risk factors. #High CV risk was defined as established
coronary artery disease, any CV disease that required prophylactic low-dose aspirin, or an estimated 10-yr CV risk of greater than 20%. +A
nonselective NSAID includes both naproxen and a nonselective NSAID.
The panel rated the use of naproxen or non-naproxen non-
selective NSAIDs as appropriate when the patient had aver-
age GI risk (i.e., <70 yr of age; no prior upper GI event; no
corticosteroids, antithrombotic agents, anticoagulants). Any
absolute benefit was too small to justify using a coxib or
co-therapy with a PPI or misoprostol in these patients.
The only factor in choosing between naproxen and non-
naproxen nonselective NSAIDs was the patient’s CV risk:
naproxen was preferred if the patient had high CV risk. The
latter recommendation was based on systematic reviews of
randomized trials and observational studies that naproxen
is associated with fewer CV events than coxibs and non-
naproxen NSAIDs (6, 9). However, one should be cautioned
that these systematic reviews were largely derived from pa-
tients with low CV risk. For example, the annual rate of CV
events in the placebo arm in the meta-analysis of coxib tri-
als was <1% and the vast majority of study subjects were
not on low-dose aspirin (6). The most plausible explanation
for the apparent heterogeneity between naproxen and non-
naproxen NSAIDs in terms of their comparative CV safety
is probably the fact that many patients on naproxen achieved
adequate inhibition of platelet COX-1 throughout the dosing
interval of the drug. In clinical practice, however, patients
with high CV risk should be on low-dose aspirin. The latter
will abolish platelet COX-1 activity, theoretically rendering
all NSAIDs different only in terms of their extent (as a func-
tion of dose) and duration (as a function of half-life and dosing
regimen) of COX-2 inhibition on the vessel wall. From this
mechanistic perspective, naproxen given to aspirin-treated
patients may behave like all other non-naproxen NSAIDs
and coxibs. Unfortunately, clinical data assessing the CV risk
of different NSAIDs with low-dose aspirin therapy are not
available. Thus, good evidence does not exist to allow clear-
cut, “evidence-based” recommendations regarding choice of
NSAIDs in low-dose aspirin users.
In a patient with high GI risk, cotherapy with a
PPI/misoprostol co-therapy was appropriate. The choice
of NSAIDs among patients requiring a gastroprotective
agent largely depended on the estimated CV risk. Non-
naproxen NSAIDs were not regarded as appropriate in any
vignette with high CV risk. The panel rated naproxen plus
a PPI/misoprostol as appropriate when the patient had high
CV risk and other GI risk factors, such as age ≥70, a prior
upper GI event, and/or concomitant pharmacological risk fac-
tors for GI bleeding. A combination of PPI/misoprostol plus
a nonselective NSAID (naproxen or non-naproxen NSAIDs)
or a PPI/misoprostol plus a coxib was rated appropriate in pa-
tients with high GI risk but average CV risk. Arguably, these
last recommendations are not entirely consistent with the cur-
rent evidence in the literature. Previous studies indicated that
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neither a nonselective NSAID plus a PPI nor a coxib alone
was sufficient to prevent recurrent ulcer bleeding among pa-
tients with a recent ulcer complication (41–43), and recent
data showed that a coxib plus a PPI was superior to a coxib
alone in patients with high GI risk (34, 44). Our category of
upper GI clinical event included both prior bleeding ulcer as
well as symptomatic ulcer. One may consider stratifying by
GI risk when choosing between coxib plus PPI/misoprostol
or nonselective NSAID plus PPI/misoprostol. The “safer”
but more expensive regimen (i.e., a coxib plus a PPI) may
not be recommended in every circumstance. The combina-
tion of a coxib plus PPI/misoprostol is recommended for
patients at very high risk (e.g., recently hospitalized for ul-
cer bleeding) but PPI/misoprostol plus nonselective NSAID
may be acceptable for patients with less serious GI risk
factors (e.g., concomitant corticosteroid therapy). No trial
specifically designed to determine whether a coxib plus a
PPI/misoprostol is superior to a nonselective NSAID plus a
PPI/misoprostol has been carried out in patients with high
GI risk.
Finally, the panel felt that no form of NSAID therapy could
be considered appropriate in patients with high CV risk and
very high GI risk (e.g., multiple GI risk factors). In this popu-
lation, non-NSAID analgesia would be recommended. If an-
tiinflammatory therapy is required, the choice of therapy will
be a trade-off between individual patient’s CV and GI risk.
The panel chose naproxen plus a PPI or misoprostol among
patients whose CV risk outweighed their GI risk (e.g., recent
myocardial infarction). If a coxib plus a PPI or misoprostol is
required to maximize gastric protection in patients with very
high GI risk as well as increased CV risk, use of the low-
est possible dose of coxibs seems prudent because the CV
toxicity of coxibs may be dose related (4, 6). A systematic
review of randomized trials found that the relative risk with
celecoxib 200 mg daily was approximately 1 (although the
confidence interval was wide) with a significant increase in
risk as the dose increased to 400 mg and 800 mg daily (6).
However, it must be emphasized that there have been no stud-
ies addressing the safety of low-dose coxibs (e.g., celecoxib
200 mg once daily) in patients with or at risk for coronary
artery disease.
Our process of developing clinical recommendations had
limitations despite the rigorous methodology used. First, di-
chotomizing nonselective NSAIDs as naproxen and non-
naproxen NSAIDs could restrict the panel in their choice
for appropriate therapy. Whether naproxen has a lower CV
hazard than other NSAIDs needs to be confirmed by ran-
domized trials as previously mentioned. In addition, not all
nonselective NSAIDs are equivalent with respect to GI safety.
For example, naproxen may have a better CV safety profile
but a higher GI risk compared with other NSAIDs. In con-
trast, diclofenac has one of the lowest odds ratios for upper
GI bleeding but it is associated with a significant increase
in CV risk (7). Although stratifying NSAIDs according to
different combinations of CV and GI safety profiles may of-
fer more treatment options, the number of vignettes needed
would be exponentially increased and render the final recom-
mendations too complex and impractical. Second, we did not
perform a comprehensive review of the benefits of NSAIDs.
It is clear that that there are competing risks and benefits of
NSAIDs. Whilst the benefits of symptomatic relief are less
easy to quantify than the risks, for many patients they are of
immense importance. Thus, the decision to prescribe must be
set in light of individual patient benefits. Third, many ratings
on patients with high CV risk largely reflect expert opinion
rather than evidence because we do not have the data from
randomized trials of the CV safety of different NSAIDs and
coxibs in patients receiving aspirin.
In conclusion, we used an evidence-based methodology
to develop a management algorithm to assist physicians in
choosing an appropriate NSAID treatment strategy in patients
with different combinations of GI and CV risks (Fig. 1). The
patient’s CV risk determines the initial choice of an NSAID
(naproxen vs. others), while the severity and number of GI
risk factors determine the need for therapy to decrease GI
complications (PPI/misoprostol, coxibs).
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